Trevi Therapeutics' Series C - II Round

Trevi Therapeutics raised a round of funding on September 05, 2018.

Trevi Therapeutics is a development-stage biotechnology company focused on developing Nalbuphine ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic and n…

Articles about Trevi Therapeutics' Series C - II Round: